KBC Group NV Grows Position in Kenvue Inc. (NYSE:KVUE)

KBC Group NV lifted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 308.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,179,185 shares of the company's stock after purchasing an additional 1,645,519 shares during the quarter. KBC Group NV owned about 0.11% of Kenvue worth $52,257,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of KVUE. SRS Capital Advisors Inc. raised its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares during the last quarter. Continuum Advisory LLC boosted its holdings in shares of Kenvue by 2,071.1% in the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after acquiring an additional 1,864 shares in the last quarter. Clarity Asset Management Inc. acquired a new position in shares of Kenvue during the fourth quarter worth about $45,000. SBI Securities Co. Ltd. purchased a new position in Kenvue during the fourth quarter worth about $46,000. Finally, Golden State Wealth Management LLC lifted its position in Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock valued at $74,000 after purchasing an additional 2,295 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE stock traded down $0.04 during trading hours on Wednesday, hitting $20.94. The company's stock had a trading volume of 10,047,401 shares, compared to its average volume of 16,087,419. The business has a fifty day moving average of $22.73 and a 200-day moving average of $22.34. The stock has a market cap of $40.17 billion, a price-to-earnings ratio of 38.08, a P/E/G ratio of 3.25 and a beta of 0.84. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the previous year, the business posted $0.28 earnings per share. The company's revenue was down 3.9% on a year-over-year basis. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.92%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on KVUE. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price for the company. UBS Group upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Finally, Barclays raised their price objective on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Kenvue has an average rating of "Hold" and a consensus price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.